HomeBusinessBiocon receives two observations from USFDA for API Manufacturing Facility in Bengaluru
spot_img

Biocon receives two observations from USFDA for API Manufacturing Facility in Bengaluru

Date:

Trending

India’s leading biopharma company, Biocon Limited on Thursday said that “It has received a Form 483 and two observations for its Small Molecules API Manufacturing facility in Bengaluru.”

In a filing with the Bombay Stock Exchange, the company said, “The Post-Approval and GMP inspection was conducted between Feb 20 and Feb 26, 2020, by the U.S. Food and Drug Administration (USFDA) at our Small Molecules API Manufacturing Facility at 20th KM, Biocon Campus, Bengaluru.”

- Advertisement -

“After the inspection, Form 483, with two observations, which are procedural in nature, was issued to the company by the USFDA,” the filing said.

“We are confident of addressing these observations expeditiously and will respond to the FDA with a corrective and Preventive Action Plan (CAPA) in a timely manner,” the company said.

“We remain committed to global standards of Quality and Compliance,” it added.

THE SNAPSHOTS, IN YOUR INBOX

Get quick snaps of everyday happening, directly in your inbox.

- Advertisement -

We don’t spam! Read our privacy policy for more info.

- Advertisement -
Krishna Mali
Krishna Mali
Founder & Group Editor of TechGraph.
spot_img

More Latest Stories

spot_img

Related Stories